Hume Kyle - Sumitomo Dainippon Insider

Sumitomo Dainippon Pharma Co Ltd -- Germany Stock  

EUR 12.78  0.12  0.93%

CFO, Executive Vice President

Mr. Hume D. Kyle is a Chief Financial Officer and Executive Vice President of Dundee Precious Metals Inc., with effective from June 6, 2011. Mr. Kyle has more than 25 years of experience as a financial executive in a number of complex, publicly traded, multinational energy and natural resource businesses. He has held a range of increasingly senior roles in public practice and private industry including Assistant Treasurer, Treasurer Vice President, Finance and Controller, and Chief Financial Officer. Most recently, Mr. Kyle served as Vice President, Treasurer and Controller, of TransAlta Corporationrationration, an 11 billion power generating company where he was responsible for providing leadership over the financial activities of the organization, principally in the areas of corporate accounting and reporting, strategic finance, treasury, taxation, and financial systems, processes and controls
  President Since 2011      
81 6 6203 5321
Kyle holds a Bachelor of Arts degree in Economics and Accounting from the University of Western Ontario and a Graduate Diploma in Public Accounting from McGill University. He is also a Chartered Accountant and a Chartered Financial Analyst.

Management Efficiency

The company has return on total asset (ROA) of 5.06 % which means that it generated profit of $5.06 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 10.1 % meaning that it generated $10.1 on every $100 dollars invested by stockholders.
The company has accumulated 558.01 M in total debt with debt to equity ratio (D/E) of 11.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Sumitomo Dainippon Pharma Co Ltd has Current Ratio of 1.94 which is within standard range for the sector.

Similar Executives

Entity Summary

Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients, food additives, veterinary medicines, diagnostics, and others. Sumitomo Dainippon Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited. Sumitomo Dainippon is traded on Frankfurt Stock Exchange in Germany.Sumitomo Dainippon Pharma Co Ltd (DPM) is traded on Frankfurt Stock Exchange in Germany. It is located in 6-8 Doshomachi 2-chome and employs 6,492 people.

Did you try this?

Run Companies Directory Now

Companies Directory

Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Hide  View All  NextLaunch Companies Directory
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Sumitomo Dainippon Pharma Co Ltd to your portfolio

Top Management

Sumitomo Dainippon P Leadership Team
Peter Nixon, Director
Jonathan Goodman, CEO, MBA
Richard Gosse, President
Colin McAnuff, Executive
John Lindsay, President
Mark Crawley, President
Peter Gillin, Director
MarieAnne Tawil, Director, MBA
Richard Howes, President
Hume Kyle, President
Anthony Walsh, Director
Garth MacRae, Director
Zebra Kasete, President, MBA
Juanita Montalvo, Director
David Rae, President
Donald Young, Director
Michael Dorfman, President
Lori Beak, President
Jeremy Kinsman, Director, MBA
Brent Johnson, President
Paul Proulx, President
Nikolay Hristov, President
Murray John, Director, MBA
Hratch Jabrayan, President

Stock Performance

Sumitomo Dainippon Performance Indicators